Medicine evaluation figures

The European Medicines Agency (EMA) publishes information on the volume and outcome of marketing authorisation and post-authorisation applications for human and veterinary medicines that it evaluates.

The documents on this page contain factual information on medicines evaluation, presented on an annual and monthly basis.

As of January 2023, the reports containing monthly figures for human medicines also include the:

• new active substances (NAS) status at the time when EMA's Committee for Medicinal Products for Human Use (CHMP) publishes an opinion; 
• number of applications withdrawn after a first CHMP opinion (e.g. during re-examination);
• number of opinions on companion diagnostics medical devices.

Please note that the monthly figures listed on this page only cover human medicines. For monthly evaluation figures on veterinary medicines, see the monthly reports of the Committee for Medicinal Products for Veterinary Use (CVMP) on CVMP: Agendas, minutes and reports.

For commentaries and analysis, see the Agency's annual reports.

For the main outcomes of the monthly plenary meetings of the Agency's seven scientific committees, see Committee highlights.

• Medicines evaluation figures: archive 2010-2015